Incyte Q4 Adj EPS Misses Estimates, But Revenues Top
(RTTNews) - Incyte Corp. (INCY) on Tuesday reported net income of $201.10 million or $0.89 per share for the fourth quarter, sharply higher than $28.46 million or $0.13 per share in the prior-year quarter.
Excluding items, adjusted net income for the quarter was $1.06 per share, compared to $0.62 per share in the year-ago quarter.
Total revenues for the quarter rose 9 percent to $1.01 billion from $926.70 million in the same quarter last year.
On average, analysts polled by Thomson Reuters expected the company to report earnings of $1.16 per share on revenues of $1.0 billion for the quarter. Analysts' estimates typically exclude special items.
Looking ahead to fiscal 2024, Incyte now projects Jakafi net product revenue in a range of $2.69 billion to $2.75 billion. Other Hematology/Oncology net product revenues are projected between $325 million and $360 million.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
Incyte Says FDA Issued CRL For Ruxolitinib Extended-release Tablets
Incyte Q1 Results Top Estimates
FTSE 100 Down 0.4% In Cautious Trade
CAC Up Slightly; Pernod Ricard Rises On Earnings
DAX Retreats After Firm Start, Down Marginally
Swiss Franc Rises Against Majors
Sensex, Nifty Retreat On US Tariff Worries
